Vipergen is a world leading provider of small molecule drug discovery services based on DNA-encoded library (DEL) technologies.
Vipergen is finding tractable hits/leads for your pharmaceutical relevant targets, using three proprietary 2nd and 3rd generation DEL technologies.
Vipergen is offering different business models, including simple Fee-For-Service.
Recent News
- Copenhagen, Denmark, November 6th, 2020 - Commercial release of the first technology for DEL screening inside a living cell - Vipergen ApS announced today the commercial release of the first technology for screening of DNA-encoded small molecule libraries (DELs) inside a living cell. This proprietary technology will significantly accelerate and improve the drug discovery process.
YoctoReactor® – Technology platform for synthesizing DNA-encoded chemical libraries
• 100% match between the DNA-code and the synthesized small molecule is ensured by purification steps after each chemical reaction (unique capability) and use of robust chemistries
Binder Trap Enrichment® – Technology platform for DEL screening in a homogeneous assay
• As a homogeneous assay, BTE delivers high fidelity and a low false positive rate by avoiding surface artifacts and the complexity of matrix binding
• Instant specificity – multiplexed screening of target and anti-targets (unique capability)
Cellular Binder Trap Enrichment® – Technology platform for DEL screening in a living cell
• As an in vivo assay, cBTE delivers lower attrition rate (unique capability)
• No need for purified active target protein – cBTE accommodates a broader target space (unique capability)
Company Details
- Employees
- 13
- Founded
- -
- Address
- Gammel Kongevej 23a, Copenhagen,1610,denmark
- Phone
- +45 2523 6680
- in****@****gen.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- vipergen.com
- Keywords
- drug discovery, DNA-encoded chemical libraries, small molecules, protein-protein interaction inhibitors, DEL screening in living cells, DELS in Cells, Molecular glue, Membrane protein inhibitors.
- HQ
- Copenhagen
Vipergen Aps Questions
Vipergen Aps's helpline number is +45 2523 6680
Vipergen Aps's website is vipergen.com
Vipergen Aps's LinkedIn profile is https://dk.linkedin.com/company/vipergen-aps
Vipergen Aps has
13 employees.
View email and phone details for 13
employees at Vipergen Aps.
Vipergen Aps's industry is
Biotechnology Research
Vipergen Aps's top competitors are
Duos,
Aurigene Pharmaceutical Services Limited,
Serengen Gmbh,
Scanpharm A/s,
Particle Analytical Aps,
Vipergen,
Specific Pharma A/s,
Saromics Biostructures Ab,
Scandion Oncology,
Gubra.
Vipergen Aps's support email address is info@vipergen.com
Vipergen Aps's categories are Biotechnology Research
Vipergen Aps's founding year is 2005
